BACKGROUND: In men with chronic prostatitis-chronic pelvic pain syndrome, treatment with alpha-adrenergic receptor blockers early in the course of the disorder has been reported to be effective in some, but not all, relatively small randomized trials. METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of alfuzosin, an alpha-adrenergic receptor blocker, in reducing symptoms in men with chronic prostatitis-chronic pelvic pain syndrome. Participation in the study required diagnosis of the condition within the preceding 2 years and no previous treatment with an alpha-adrenergic receptor blocker. Men were randomly assigned to treatment for 12 weeks with either 10 mg of alfuzosin per day or placebo. The primary outcome was a reduction of at least 4 points (from baseline to 12 weeks) in the score on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) (range, 0 to 43; higher scores indicate more severe symptoms). A 4-point decrease is the minimal clinically significant difference in the score. RESULTS: A total of 272 eligible participants underwent randomization, and in both study groups, 49.3% of participants had a decrease of at least 4 points in their total NIH-CPSI score (rate difference associated with alfuzosin, 0.1%; 95% confidence interval, -11.2 to 11.0; P=0.99). In addition, a global response assessment showed similar response rates at 12 weeks: 33.6% in the placebo group and 34.8% in the alfuzosin group (P=0.90). The rates of adverse events in the two groups were also similar. CONCLUSIONS: Our findings do not support the use of alfuzosin to reduce the symptoms of chronic prostatitis-chronic pelvic pain syndrome in men who have not received prior treatment with an alpha-blocker. (ClinicalTrials.gov number, NCT00103402.) 2008 Massachusetts Medical Society
RCT Entities:
BACKGROUND: In men with chronic prostatitis-chronic pelvic pain syndrome, treatment with alpha-adrenergic receptor blockers early in the course of the disorder has been reported to be effective in some, but not all, relatively small randomized trials. METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of alfuzosin, an alpha-adrenergic receptor blocker, in reducing symptoms in men with chronic prostatitis-chronic pelvic pain syndrome. Participation in the study required diagnosis of the condition within the preceding 2 years and no previous treatment with an alpha-adrenergic receptor blocker. Men were randomly assigned to treatment for 12 weeks with either 10 mg of alfuzosin per day or placebo. The primary outcome was a reduction of at least 4 points (from baseline to 12 weeks) in the score on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) (range, 0 to 43; higher scores indicate more severe symptoms). A 4-point decrease is the minimal clinically significant difference in the score. RESULTS: A total of 272 eligible participants underwent randomization, and in both study groups, 49.3% of participants had a decrease of at least 4 points in their total NIH-CPSI score (rate difference associated with alfuzosin, 0.1%; 95% confidence interval, -11.2 to 11.0; P=0.99). In addition, a global response assessment showed similar response rates at 12 weeks: 33.6% in the placebo group and 34.8% in the alfuzosin group (P=0.90). The rates of adverse events in the two groups were also similar. CONCLUSIONS: Our findings do not support the use of alfuzosin to reduce the symptoms of chronic prostatitis-chronic pelvic pain syndrome in men who have not received prior treatment with an alpha-blocker. (ClinicalTrials.gov number, NCT00103402.) 2008 Massachusetts Medical Society
Authors: J Curtis Nickel; Michel Pontari; Timothy Moon; Marc Gittelman; Gholam Malek; Jean Farrington; Jay Pearson; David Krupa; Mark Bach; Jennifer Drisko Journal: J Urol Date: 2003-04 Impact factor: 7.450
Authors: Kathleen J Propert; Richard B Alexander; J Curtis Nickel; John W Kusek; Mark S Litwin; J Richard Landis; Leroy M Nyberg; Anthony J Schaeffer Journal: Urology Date: 2002-06 Impact factor: 2.649
Authors: M McNaughton Collins; M A Pontari; M P O'Leary; E A Calhoun; J Santanna; J R Landis; J W Kusek; M S Litwin Journal: J Gen Intern Med Date: 2001-10 Impact factor: 5.128
Authors: J Curtis Nickel; Joe Downey; Janet Clark; Richard W Casey; Peter J Pommerville; Jack Barkin; Gary Steinhoff; Gerald Brock; Allan B Patrick; Stanley Flax; Bernard Goldfarb; Bruce W Palmer; Joseph Zadra Journal: Urology Date: 2003-10 Impact factor: 2.649
Authors: Anthony J Schaeffer; J Richard Landis; Jill S Knauss; Kathleen J Propert; Richard B Alexander; Mark S Litwin; J Curtis Nickel; Michael P O'Leary; Robert B Nadler; Michel A Pontari; Daniel A Shoskes; Scott I Zeitlin; Jackson E Fowler; Carissa A Mazurick; Lori Kishel; John W Kusek; Leroy M Nyberg Journal: J Urol Date: 2002-08 Impact factor: 7.450
Authors: J Curtis Nickel; Dean A Tripp; Shannon Chuai; Mark S Litwin; Mary McNaughton-Collins; J Richard Landis; Richard B Alexander; Anthony J Schaeffer; Michael P O'Leary; Michel A Pontari; Paige White; Christopher Mullins; Leroy Nyberg; John Kusek Journal: BJU Int Date: 2007-10-08 Impact factor: 5.588
Authors: Phaik Yeong Cheah; Men Long Liong; Kah Hay Yuen; Chu Leong Teh; Timothy Khor; Jin Rong Yang; Hin Wai Yap; John N Krieger Journal: J Urol Date: 2003-02 Impact factor: 7.450
Authors: Michel A Pontari; John N Krieger; Mark S Litwin; Paige C White; Rodney U Anderson; Mary McNaughton-Collins; J Curtis Nickel; Daniel A Shoskes; Richard B Alexander; Michael O'Leary; Scott Zeitlin; Shannon Chuai; J Richard Landis; Liyi Cen; Kathleen J Propert; John W Kusek; Leroy M Nyberg; Anthony J Schaeffer Journal: Arch Intern Med Date: 2010-09-27
Authors: Dominik S Schoeb; Daniel Schlager; Martin Boeker; Ulrich Wetterauer; Martin Schoenthaler; Thomas R W Herrmann; Arkadiusz Miernik Journal: World J Urol Date: 2017-06-13 Impact factor: 4.226